A Comparison Between Radiolabeled Fluorodeoxyglucose Uptake and Hyperpolarized (13)C-labeled Pyruvate Utilization As Methods for Detecting Tumor Response to Treatment

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2009 Jun 2

PMID 19484146

Citations 68

Authors

Timothy H Witney

Mikko I Kettunen

Samuel E Day

De-En Hu

Andre A Neves

Ferdia A Gallagher

Sandra M Fulton

Kevin M Brindle

Affiliations

Soon will be listed here.

Abstract

Detection of early tumor responses to treatment can give an indication of clinical outcome. Positron emission tomography measurements of the uptake of the glucose analog, [(18)F] 2-fluoro-2-deoxy-D-glucose (FDG), have demonstrated their potential for detecting early treatment response in the clinic. We have shown recently that (13)C magnetic resonance spectroscopy and spectroscopic imaging measurements of the uptake and conversion of hyperpolarized [1-(13)C]pyruvate into [1-(13)C]lactate can be used to detect treatment response in a murine lymphoma model. The present study compares these magnetic resonance measurements with changes in FDG uptake after chemotherapy. A decrease in FDG uptake was found to precede the decrease in flux of hyperpolarized (13)C label between pyruvate and lactate, both in tumor cells in vitro and in tumors in vivo. However, the magnitude of the decrease in FDG uptake and the decrease in pyruvate to lactate flux was comparable at 24 hours after drug treatment. In cells, the decrease in FDG uptake was shown to correlate with changes in plasma membrane expression of the facilitative glucose transporters, whereas the decrease in pyruvate to lactate flux could be explained by an increase in poly(ADP-ribose) polymerase activity and subsequent depletion of the NAD(H) pool. These results show that measurement of flux between pyruvate and lactate may be an alternative to FDG-positron emission tomography for imaging tumor treatment response in the clinic.

Citing Articles

Hyperpolarized Carbon 13 MRI: Clinical Applications and Future Directions in Oncology.

Deen S, Rooney C, Shinozaki A, McGing J, Grist J, Tyler D Radiol Imaging Cancer. 2023; 5(5):e230005.

PMID: 37682052 PMC: 10546364. DOI: 10.1148/rycan.230005.

Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo.

Dzien P, Mackintosh A, Malviya G, Johnson E, Soloviev D, Brown G Cancer Metab. 2023; 11(1):14.

PMID: 37679822 PMC: 10486058. DOI: 10.1186/s40170-023-00314-2.

Hyperpolarized Carbon-13 MRI in Breast Cancer.

Woitek R, Brindle K Diagnostics (Basel). 2023; 13(13.

PMID: 37443703 PMC: 10340200. DOI: 10.3390/diagnostics13132311.

Neurons require glucose uptake and glycolysis in vivo.

Li H, Guglielmetti C, Sei Y, Zilberter M, Le Page L, Shields L Cell Rep. 2023; 42(4):112335.

PMID: 37027294 PMC: 10556202. DOI: 10.1016/j.celrep.2023.112335.

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.

Chakraborty K, Mondal J, An J, Park J, Lee Y Pharmaceutics. 2023; 15(3).

PMID: 36986832 PMC: 10054444. DOI: 10.3390/pharmaceutics15030971.

References

Cremerius U, Effert P, Adam G, Sabri O, Zimmy M, Wagenknecht G . FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998; 39(5):815-22. View

Day S, Kettunen M, Gallagher F, Hu D, Lerche M, Wolber J . Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med. 2007; 13(11):1382-7. DOI: 10.1038/nm1650. View

Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T . Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996; 14(3):700-8. DOI: 10.1200/JCO.1996.14.3.700. View

Neves A, Brindle K . Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta. 2006; 1766(2):242-61. DOI: 10.1016/j.bbcan.2006.10.002. View

Barrington S, ODoherty M . Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003; 30 Suppl 1:S117-27. DOI: 10.1007/s00259-003-1169-2. View

van Waarde A, Shiba K, de Jong J, Ishiwata K, Dierckx R, Elsinga P . Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med. 2007; 48(8):1320-6. DOI: 10.2967/jnumed.107.042085. View

Weissleder R, Pittet M . Imaging in the era of molecular oncology. Nature. 2008; 452(7187):580-9. PMC: 2708079. DOI: 10.1038/nature06917. View

Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber W . Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005; 23(30):7445-53. DOI: 10.1200/JCO.2005.06.965. View

Stahl A, Ott K, Schwaiger M, Weber W . Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging. 2004; 31(11):1471-8. DOI: 10.1007/s00259-004-1626-6. View

10.

Zhuang H, Pourdehnad M, Lambright E, Yamamoto A, Lanuti M, Li P . Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42(9):1412-7. View

11.

Zhou R, Vander Heiden M, Rudin C . Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res. 2002; 62(12):3515-20. View

12.

Wieman H, Wofford J, Rathmell J . Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007; 18(4):1437-46. PMC: 1838986. DOI: 10.1091/mbc.e06-07-0593. View

13.

Weber W, Ott K, Becker K, Dittler H, Helmberger H, Avril N . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19(12):3058-65. DOI: 10.1200/JCO.2001.19.12.3058. View

14.

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

15.

Su H, Bodenstein C, Dumont R, Seimbille Y, Dubinett S, Phelps M . Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19):5659-67. DOI: 10.1158/1078-0432.CCR-06-0368. View

16.

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P . Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol. 2001; 19(2):414-9. DOI: 10.1200/JCO.2001.19.2.414. View

17.

Strauss L . Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996; 23(10):1409-15. DOI: 10.1007/BF01367602. View

18.

Cheng Z, Levi J, Xiong Z, Gheysens O, Keren S, Chen X . Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem. 2006; 17(3):662-9. PMC: 3191878. DOI: 10.1021/bc050345c. View

19.

Diederichs C, Staib L, Glatting G, Beger H, Reske S . FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998; 39(6):1030-3. View

20.

Brindle K . New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008; 8(2):94-107. DOI: 10.1038/nrc2289. View